文献速递血脂与心血管预防心力衰竭与心肌病心律失常

定义肿瘤试验中的心血管终点:挑战与机遇:美国心脏协会科学声明

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.
PubMed 文献 · Circulation · 2026-06-15

该科学声明由美国心脏协会发布,旨在为当代肿瘤临床试验中心血管终点的系统选择、严格表征与裁定提供标准框架。声明将药物特异性机制与终点选择关联,标准化心力衰竭、心律失常、心肌炎及血栓事件等不良心血管事件的定义,并讨论主要不良心脏事件、临床事件与替代终点。声明还提供前瞻性监测、去中心化与混合试验设计、独立终点裁定及竞争风险与迟发毒性统计方法的实践指导。

要点

  • 肿瘤治疗可经血管、心肌或代谢途径产生心血管毒性,影响治疗与预后。
  • 声明提出将药物机制与终点选择关联,并标准化心衰、心律失常、心肌炎和血栓事件定义。
  • 建议采用前瞻性监测、独立终点裁定及竞争风险统计方法处理迟发毒性。

核心结论

  • 通过统一肿瘤试验中的心血管终点评估,可增强风险分层、促进监管接受并支持临床决策,最终在支持肿瘤治疗创新的同时改善患者安全。

研究设计与样本

  • 美国心脏协会科学声明,基于心血管医学与心血管临床试验进展,提出肿瘤试验中心血管终点的选择、表征与裁定框架。

主要发现

  • 肿瘤治疗相关心血管毒性可表现为血管、心肌或代谢途径,可能限制肿瘤治疗使用并不利影响结局。
  • 肿瘤临床试验可提供心血管安全信号数据,但定义不一致和事件表征方法差异限制了进展。

关键数值与推荐

  • 声明标准化了心力衰竭、心律失常、心肌炎和血栓事件等不良心血管事件的定义。
  • 声明讨论了主要不良心脏事件、临床事件和替代终点的定义,以及与常见不良事件术语标准(CTCAE)和患者报告结局对齐的策略。
  • 声明提供前瞻性监测、去中心化与混合临床试验设计、独立终点裁定以及竞争风险和迟发毒性统计方法的实践指导。

临床怎么用

  • 在肿瘤临床试验中系统选择、严格表征并裁定心血管终点,以评估心血管安全信号。
  • 将药物特异性机制与终点选择关联,并标准化不良心血管事件定义。
  • 采用前瞻性监测、独立终点裁定及竞争风险统计方法处理迟发毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The unprecedented expansion of approved oncology therapies has prolonged survival and transformed the prognosis for many patients diagnosed with cancer. However, cancer treatments may be associated with cardiovascular toxicities that manifest through vascular, myocardial, or metabolic pathways, potentially limiting the use of cancer therapeutics and adversely affecting outcomes. Oncology clinical trials provide an important opportunity to evaluate cardiovascular safety signals by generating data on the incidence, timing, and spectrum of toxicities. However, progress has been limited by inconsistent definitions and variable approaches to event characterization. This scientific statement aligns the advances in cardiovascular medicine and cardiovascular clinical trials to provide criteria for systematic selection, rigorous characterization, and adjudication of cardiovascular endpoints in contemporary oncology trials. The proposed framework links drug-specific mechanisms to endpoint selection and standardizes the approach to definitions of adverse cardiovascular events, including heart failure, arrhythmias, myocarditis, and thrombotic events. Definitions of major adverse cardiac events, clinical events, and surrogate endpoints are discussed, along with strategies for alignment with the Common Terminology Criteria for Adverse Events and patient-reported outcomes. Practical guidance is provided for prospective surveillance, decentralized and hybrid clinical trial designs, independent endpoint adjudication, and statistical approaches to competing risks and late-emerging toxicities. By harmonizing cardiovascular endpoint assessment across oncology trials, this scientific statement aims to enhance risk stratification, facilitate regulatory acceptance, and inform clinical decision-making, ultimately improving patient safety while supporting innovation in cancer therapeutics.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Barac A, Guha A, Fleming TR, et al. Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association. Circulation. 2026. PMID: 42296446. doi:10.1161/CIR.0000000000001417

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。